New gel could ease painful skin growths
NCT ID NCT07552077
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a gel called PTX-022 (sirolimus) on people aged 6 and older with angiokeratomas, which are small, raised skin spots. The study will check if the gel is safe and helps improve the appearance of these spots. Fifteen participants will apply the gel and be monitored for side effects and changes in their skin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sirolimus topical gel (PTX-022)
- What this could lead to
- If successful, this gel could offer a non-invasive treatment option for angiokeratomas, potentially reducing the need for more aggressive procedures.
- What could go wrong
- This is a small, early-phase trial with only 15 participants, so results may not apply widely. The gel may cause skin irritation or not improve the condition significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOKERATOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleaver Medical Group
RECRUITINGDawsonville, Georgia, 30534, United States
-
Epiphany Dermatology
RECRUITINGSouthlake, Texas, 76092, United States
-
Unified Health
NOT_YET_RECRUITINGSherman Oaks, California, 91403, United States
-
Vividia Dermatology
NOT_YET_RECRUITINGLas Vegas, Nevada, 89148, United States